Pharsight

Zepzelca patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7763615 JAZZ Ecteinascidin analogs for use as antitumour agents
Dec, 2029

(5 years from now)

Zepzelca is owned by Jazz.

Zepzelca contains Lurbinectedin.

Zepzelca has a total of 1 drug patent out of which 0 drug patents have expired.

Zepzelca was authorised for market use on 15 June, 2020.

Zepzelca is available in powder;intravenous dosage forms.

Zepzelca can be used as treatment of adult patients with small cell lung cancer (sclc) with disease progression on or after platinum-based chemotherapy..

Drug patent challenges can be filed against Zepzelca from 15 June, 2024.

The generics of Zepzelca are possible to be released after 13 December, 2029.

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 15, 2025
Orphan Drug Exclusivity(ODE-304) Jun 15, 2027

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using LURBINECTEDIN ingredient

NCE-1 date: 15 June, 2024

Market Authorisation Date: 15 June, 2020

Treatment: Treatment of adult patients with small cell lung cancer (sclc) with disease progression on or after platinum-based chemotherapy.

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

ZEPZELCA family patents

Family Patents